| [1] |
Perou CM,Sorlie T,Eisen M B,et al.Molecular portrait of human breast tumors.Nature,2000,406:747-752.
|
| [2] |
Kapp AV,Jeffrey SS,Lanferod A,et al.Discovery and validation of breast cancer subtypes.BMC Genomics,2007,8:101.
|
| [3] |
Carey LA,Perou CM,Livasy CA,et al.Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study.JAMA,2006,295:2492-2502.
|
| [4] |
Carey LA,Dees EC,Sawyer LR,et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res,2007,13:2329-2334.
|
| [5] |
Fulford LG,Reis Filho JS,Ryder K,et al.Basal-like gradeⅢinvasive ductal carcinoma of the breast:patterns of metastasis and long-term survival.Breast Cancer Res,2007,9:R4.
|
| [6] |
Livasy CA,Karaca G,Nanda R,et al.Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.Mod Pathol,2006,19:264-271.
|
| [7] |
Fulford LG,Easton DF,Reis Filho JS,et al.Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast.Histopathology,2006,49:22-34.
|
| [8] |
Jones C,Nonni A V,Fulford L,et al.CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation.Br J Cancer,2001,85:422-427.
|
| [9] |
Laakso M,Loman N,Borg A,et al.Cytokeratin 5/14-positive breast cancer:true basal phenotype cofined to BRCA1 tumors.Mod Pathol,2005,18:1321-1328.
|
| [10] |
Paredes J,LopesN,Milanezi F,et al.P-cadherin and cytokeratin 5:useful adjunct markers to distinguish basal-like ductal carcinomas in situ.Virchows Arch,2007,450:73-80.
|
| [11] |
Olivier M,Langerod A,Carrieri P,et al.The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer.Clin Cancer Res,2006,12:1157-1167.
|
| [12] |
Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.Clin Cancer Res,2004,10:5367-5374.
|
| [13] |
Matos I,Dufloth R,Alvarenga M,et al.p63,cytokeratin 5,and P-cadherin:three molecular markers to distinguish basal phenotype in breast carcinomas.Virchows Arch,2005,447:688-694.
|
| [14] |
Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.Clin Cancer Res,2004,10:5367-5374.
|
| [15] |
Kreike B,van Kouwenhove M,Horlings H,et al.Gene expression profiling and histopathological characterization of triplenegative/basal-like breast carcinomas.Breast Cancer Res,2007,9:R65.
|
| [16] |
皋岚湘,杨光之,丁华野,等.基底细胞样性浸润性乳腺癌病理形态观察.中华病理学杂志,2008,37:83-87.
|
| [17] |
Rakha EA,Reis Filho JS,Ellis O.Basal-like breast cancer:a critical review.J Clin Oncol,2008,26:2568-2581.
|
| [18] |
Hicks DG,Short SM,Prescott NL,et al.Breast cancers with brain metastases are more likely to be estrogen receptor negative,express the basal cytokeratin CK5/6,and overexpress HER2 or EGFR.Am J Surg Pathol,2006,30:1097-1104.
|
| [19] |
Finn RS,Dering J,Ginther C,Wilson CA,et al.Dasatinib,an orally active small molecule inhibitor of both the src and abl kinases,selectively inhibits growth of basal-type/triple-negative breast cancer cell lines growing in vitro.Breast Cancer Res Treat,2007,105:319-326.
|
| [20] |
Huang F,Reeves K,Han X,et al.Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib:rationale for patient selection.Cancer Res,2007,67:2226-2238.
|
| [21] |
Gluz O,Liedtke C,Gottschalk N,et al.Triple-negative breast cancer:current status and future directions.Ann Oncol,2009,20:1913-27.
|
| [22] |
Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer.J Clin Oncol,2008,26:1275-1281.
|
| [23] |
Diallo-Danebrock R,Ting E,Gluz O,et al.Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy.Clin Cancer Res,2007,13:488-497.
|
| [24] |
Lin Y,Lin S,Watson M,et al.A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.Breast Cancer Res Treat,2009,123:691-699.
|
| [25] |
Rakha EA,El Sayed ME,Green AR,et al.Breast carcinoma with basal differentiation:a proposal for pathology definition based on basal cytokeratin expression.Histopathology,2007,50:434-438.
|
| [26] |
Burness ML,Grushko TA,Olopade OI.Epidermal growth factor receptor in triple-negative and Basal-like breast cancer:promising clinical target or only a marker?Cancer J.2010,16:23-32.
|
| [27] |
Scully R,Livingston DM.In search of the tumour-suppressor functions of BRCA1 and BRCA2.Nature,2000,408:429-432.
|
| [28] |
Turner NC,Reis Filho J S,Russell AM,et al.BRCA1 dysfunction in sporadic basal-like breast cancer.Oncogene,2007,26:2126-2132.
|
| [29] |
Richardson AL,Wang ZC,De Nicolo A,et al.X chromosomal abnormalities in the basal-like human breast cancer.Cancer Cell,2006,9:121-132.
|
| [30] |
Murphy CG,Moynahan ME.BRCA Gene Structure and Function in Tumor Suppression:A Repair-Centric Perspective.Cancer J,2010,16:39-47.
|